Allogeneic bone marrow transplantation for multiple myeloma

S. Tura, M. Cavo, G. Rosti, G. Bandini, M. Gobbi, M. Grimaldi, M. C. Miggiano, L. Albertazzi, M. A. Bonelli

Research output: Contribution to journalArticlepeer-review


Seventeen patients received marrow transplants from their HLA-matched, MLC-negative, sibling donors. Nine patients had progressive disease not responding to conventional treatments, while the other 8 patients were rated as responders. The most frequently used conditioning regimen consisted of total body irradiation and high-dose multi-agent chemotherapy with cyclophosphamide plus either oral melphalan (5 cases) or BCNU (1 case) on both these drugs (7 cases). Twelve patients were valuable for response to BTM: 7 of them (6 responders and 1 with advanced refractory MM) entered complete remission, while 5 had a sustained decrease in tumor mass that ranged between 72% and 93%. Eleven patients died of transplant-related causes, 1 of them with signs of progressive disease. The remaining 6 patients are alive and 5 of them maintain a complete remission status 4 to 67 (median 36) months after BMT.

Original languageEnglish
Pages (from-to)106-108
Number of pages3
JournalBone Marrow Transplantation
Issue numberSUPPL. 4
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Allogeneic bone marrow transplantation for multiple myeloma'. Together they form a unique fingerprint.

Cite this